ANTI-OXIDANT COMPOUND FOR ACTIVATING NOVEL HYDROGEN PEROXIDE AND PHARMACEUTICAL COMPOSITION USING SAME
The present invention refers to antioxidant activity of the compound showing using the same relates to a pharmaceutical vaginal composition in, more specifically for producing phenol (bioactive) bioactive H2 O2-removal nick S can be phenyl boronate relates to (phenylboronic ester). [...] hydrogel (H2 O2) has and an integral oxidative metabolic product adaptive of organisms, intellectdevelopment and for growth that is required to make serves as messenger in cell signaling. H2 O2 the active oxygen kind (Reactive oxygen species, ROS) and one kind of, the in addition (hypochloride) lung rock new Oh nitric acid saltthe gun Oh the chlorine it buys the salt and the high (peroxinitrite), hydroxyl radical as described in the examples is precursors of ROS of toxicity. H2 O2, such as oxidative stress which decreases accumulation of many that response and irritations which evidence, this cancer, diabetes, cardiovascular disorders, and ischemia-reperfusion (ischemia-reperfusion, I/R) damage and the like (onset) onset of various pathological conditions is connected to the semiconductor layer. associated high and progression. I/R damage (Acute Coronary Syndrome) acute coronary syndrome, ischemic damage elongation at the micro computer calculates a, right circuit alcoholic beverage resuscitation, excessive formation of in a vessel such as. viewed at variety of clinical conditions. A reperfusion of ischemic tissue blood I/R impairment to, fgfr5, forms of ROS (Reactive oxygen species) in a large amount of H2 O2 is to derive, causing the extraction of the and cell damage, such as oxidative stress, . highest frequency in addition further tissue damage. Thus H2 O2, such as oxidative stress the data structure for diseases related to the target and, a high concentration of H2 O2 a I/R the site of injury is characterized scale, and direct targeted therapy for or more generally antioxidant therapy will stream through large. 4-hydroxyl dichlorobenzyl alcohol (HBA) gastrodia elata BLUME (Gastrodia elata) main active ingredient selected from acryl, gastrodia elata BLUME a Asian seizure diseases and inflammation in a hub for treating malfunctions of the weather radar are material the free surfaces. Coronary that is active antioxidant has HBA sinceritybrain damage bowel disease such as ischemic and oxidative stress illnesses related to protected against make role. In addition the HBA phenol hydroxyl group (superoxide) superoxide due to cold chamber and is for preparing hybridoma producing the anti-erase number (scavenger). As and therapeutic antioxidant HBA interest as against the use of but at high temperature, the HBA H2 O2 which cannot erase, short blood circulation time, a plate is the auto gain adjustment clinical application. , Such as oxidative stress damage, to prevent or treat useful new compounds to develop, it is necessary that. These compounds are ROS-induced oxidative stress and, for the prevention or treatment of inflammatory response can be useful in.. As described to, the present invention refers to hydrogel may be activated by [...] antioxidant nick S boronate (esters) (boronic esters) is characterised in that, the compounds of these including composition and, for example for the treatment of ischemic/reperfusion injury, as antioxidant, said composition characterized by a use including antioxidant. The present invention refers to 4 - (hydroxymethyl) phenyl at step Nick ester (4 - (hydroxymethyl) phenylboronic ester) provides. The present invention refers to in addition the present invention according to (esters) (boronic esters) including a nick S boronate provides microparticles. The present invention refers to in addition the present invention according to (esters) (boronic esters) and/ or ornick S boronate including microparticles provides a pharmaceutical compositions. The present invention refers to in addition the present invention according to ester (esters), microparticle or composition including drug delivery system which is. The present invention refers to in addition subject oxidative stress damage due to, for the prevention or treatment of provides a method, said method the therapeutically effective amount of a the present invention according to ester (esters), the present invention according to microparticles, or the present invention according to therapeutically includes administering to the subject a, the (boronic esters) boronate said nick S 4-hydroxybenzyl alcohol (HBA) in received in a body subject to is released starting materials are at least partially decomposed, damage due to, such as oxidative stress can be to treat or prevent. The present invention refers to in addition a subject's body part at least in which the part defined as inhibiting formation of ROS (Reactive oxygen species) provides method or preventing, said method the therapeutically effective amount of a the present invention according to ester (esters), the present invention according to microparticles, and/or the present invention according to therapeutically includes administering to the subject, the subject said nick S boronate HBA in received in a body (boronic esters) is released which is decomposed into least in part in order to, thus a subject's body in at least a portion of layer, or comprises a non-ROS be suppressed or otherwise prevented.. The present invention refers to in addition in tissues or organs for transplantation ischemic damage or reperfusion injury and method for reducing, before implanting an, or implant a after implantation or during (esters) ester the present invention according to, the present invention according to microparticles, and/or the present invention according to composition to tissue or organ provides including method, thereby the ischemic damage organ of a and is combined with the support body and reperfusion method provides for. The present invention refers to in addition of ischemia-reperfusion of a subject cell death associated with impaired provides method for reducing, or the present invention according to ester (esters), the present invention according to microparticles, or the present invention according to an amount effective composition for treating administering to the subject a provides including method, thus the associated cell death of ischemia-reperfusion injury method provides is reduced. The present invention refers to in addition of ischemia-reperfusion of a subject associated with inflammatory provides method for reducing, or the present invention according to ester (esters), the present invention according to microparticles, and/or the present invention according to an amount effective composition for treating administering to the subject a provides including method, thus the of ischemia-reperfusion injury associated with inflammation provides method for reducing. According to one embodiment, in addition the ester (esters) (diol) diol, triol (triol), tetra ol (tetraol), pen towel (pentaol), chemical formula (hexaol) and a polyol (polyol) more hydroxyl group selected from the group comprising includes an alcohol phase, said alcohol and [...]at hour methyl phenyl step Nick hydroxy 4 - (4 - (hydroxymethyl) phenylboronic acid) has a (boronic esters) nick S covalently to form a constitution: this level shifter circuit. According to other embodiment, said alcohol or diol includes alkanols tree. According to another embodiment, said acid and alcohol are 1,3-propanediol (1,3-propanediol) or 2 - (hydroxymethyl) - 2-methyl propane -1,3-diol (2 - (hydroxymethyl) - 2-methylpropane-1,3-diol) includes. According to another embodiment, the (boronic esters) boronate said nick S 4 - (5-hydroxymethyl) - 1, 3, 2-methyl-5-one-2- d jade company barley difficulty ) phenyl methanol) (4 - (5 - (hydroxymethyl) - 5-methyl-1, 3, 2-dioxaborinan-2-yl) phenyl methanol) or or 4 - (1, 3, 2- d jade company barley difficulty -2-one) phenyl methanol) (4 - (1, 3, 2-dioxaborinan-2-yl) phenyl methanol) includes. According to another embodiment, said micro particles is biodegradable preferably biocompatible. According to another embodiment includes a polymer microparticles, or liposome. According to another embodiment, said PLA polymer (poly (lactic acid), PGA (poly (glycolic acid)), PLGA (poly (lactic-co-glycolic acid)), and PCL (poly (caprolactone-ε) from the group comprising includes the select at least one. According to another embodiment, said, such as oxidative stress damage, acute coronary syndrome (Acute Coronary Syndrome), ischemia between, elongation at ischemia, ischemia of the brain, coronary artery disease, right circuit alcoholic beverage resuscitation, systemic emptiness the characteristic which will break /reperfusion and/or vascular of associated with such as thromboembolic is ischemic/reperfusion injury. According to another embodiment, said method ischemic/reperfusion associated with alveolar damage reduces the cell death or inflammatory. Surface according another embodiment, the ROS includes type peroxide or superoxide. According to another embodiment, a heart tissue said tissues or organs, heart, kidney tissue, elongated, hypercholesterolemia tissue, liver, waste tissue, waste, pancreatic, the pancreatic tissue, wind tissue, field, Thymus, bone, cartilage, muscle tissue, tendon, cornea, epithelial tissues, skin, heart valve, neurons (neuronal cells), neural, endothelial tissue, arterial or venous, etc.. According to another embodiment, said subject is a mammal. According to another embodiment, a tissue and said is derived in a mammal. According to another embodiment is human mammalian said. According to another embodiment, said method heart, or of new nerve cells reduces the apoptosis. According to another embodiment, the method PV loop by ultrasonic and/or a cardiac assays which evaluates the. dysfunction surface of the heart. According to another embodiment, a therapeutically in a subject said method and/or inductive TNF-α. reduce the level NOS (nitric oxide synthase). According to another embodiment, said control group the treated therapeutically not is level inflammatory present in the subject. According to another embodiment, said acute coronary syndromes or inflammatory apoptosis of cells (Acute Coronary Syndrome), ischemia between, elongation at ischemia, ischemia of the brain, coronary artery disease, resuscitation of and/or vascular right circuit alcoholic beverage constitution: associated with thromboembolic. According to another embodiment, the present invention refers to 4 - (hydroxymethyl) phenyl at step Nick ester (4 - (hydroxymethyl) phenylboronic ester) antioxidant and a method for of using these compositions as number provides. The present invention compositions and defined by a provided of the following materials in the embodiment is produced or discrete associated with. Detailed description of the invention of the present invention other types and advantages are made apparent in claim and will. The present invention refers to in addition subject oxidative stress damage due to, for the prevention or treatment of provides a method, said method the therapeutically effective amount of a the present invention according to ester (esters), the present invention according to microparticles, and/ or or therapeutically the present invention according to, comprising the administered to a subject, the subject said received in a body (boronic esters) nick S boronate 4-hydroxybenzyl alcohol (HBA) is released in starting materials are at least partially decomposed to, damage due to, such as oxidative stress can be to treat or prevent. The present invention refers to in addition a subject's body part at least in which the part defined as inhibiting formation of ROS (Reactive oxygen species) provides method or preventing, said method the therapeutically effective amount of a the present invention according to ester (esters), the present invention according to microparticles, and/or the present invention according to therapeutically includes administering to the subject, the subject said nick S boronate HBA in received in a body (boronic esters) is released which is decomposed into least in part in order to, thus a subject's body in at least a portion of layer, or comprises a non-ROS be suppressed or otherwise prevented.. Preferred embodiment for of the following the present invention as detailed is prepended a drawing with better if is it will be appreciated. To diagram in of the present invention, was appends the preferred embodiment drawing current. However the present invention refers to drawing a disclosure with accurate the first deoxygenator embodiment is not limited and means arranged that. is unequivocally associated with the. Also 1 (also 1a-1b) the H2 O2 BRAP generation of scavenging antioxidant is formed inside the tie. shown. (Also 1a:H2 O2 antioxidant that is activated by BRAP as prodrugs exemplary synthetic routes for quantity of water and water pressure. Also 1b:H2 O2-mediated hydrolysis before and after BRAP1 H NMR spectrum.) Also 2 (also 2a-2c) of the BRAP H2 O2 erase effect is formed inside the tie. shown. (Also 2a:H2 O2 BRAP exemplary change in the presence of UV storage amount. Also 2b: mixtures of varying concentrations by BRAP H2 O2 erase. H2 O2 solution (10 μΜ) the 1 is mixed with and a BRAP or HBA minutes, chemical intensity of the light emission (diphenyl oxalate) (10 mg) [...][...] and (rubrene) (1 mg) by adding a measure the. * p < 0.01, **p < 0.001 H2 O2 associated with the group can be compared (n=4/group). Also 2C: acid 72 hours under conditions of BRAP1 H NMR spectrum (pH =3)) Also 3 (also 3a-3b) (RAW264.7) macrophage of a mouse (also 3a) and (3b also) ARVC [...] MTT in that can be evaluated by using the same, capable of biocompatible profile displayed in a diagram in set of histograms is formed inside the tie.. Also 4 (also 4a-4f) in the in vitro antioxidant and antiinflammatory effect BRAP shown in the graphs and histograms is formed inside the tie. as illustrated at and Image. (Also 4a-4b: LPS (1 μg/ml) (also 4a) or H2 O2 (250 µm) (also 4b) that is activated by in macrophages, mouse, which display inhibitory effects on generating ROS. Creating a ROS using flow as indications of fluorescent DCF adopted law portion is fixed on the heated at a temperature not higher than (flow cytometry). In the fluorescence excitations and in 480 nm 530 nm was analyzed in one cell 10000 ray emission. Also 4c:H2 O2 those phosphors activated by in cardiac muscle cells of adult RAT BRAP and protective effect of (Rats). V=vehicle, * < 0.05 vs V + H2 O2 (n=4) also 4D: LPS-activated in a cell, * p NO, which display inhibitory effects on generation of < 0.01, < 0.001 LPS **p compared group processing (n=4/group). Also 4e-4f: LPS activated mouse macrophage TNF-α in a cell (also 4e) and iNOS BRAP (also 4f) for generation of the inhibitory effect of. <0.001 LPS processing group than **p (n=4/group)). Also 5 (also 5a-5d) I/R of the liver (1 time ischemia/reperfusion time 12) impairment to BRAP of beneficial effect set of histograms Image and is formed inside the tie. as illustrated at. (Also 5a: HBA BRAP or after injection of a, mouse misdiagnosis dyeing - [...] for between (hematoxylin-eosin (H/E) staining) dyeing and DHE TUNEL dyeing. Also 5b-5d: quantitative analysis of serum ALT level (also 5b), cut caspase-3 expression of proteins (also 5c), and subsequent damage I/R expression of proteins (also 5d)* p TNF-α < 0.01 Veh I/R compared. † P compared to < 0.05 HBA I/R (n=3-4 group). Actin expression of proteins for a protein-load. (internal control) been used as control null) Also 6 (also 6a-6f) after the I/R, heart functions Image and effect of BRAP set of histograms is formed inside the tie. as illustrated at. (Also 6a:2 weeks after damage I/R administering BRAP heart ef, a fluid consumption can be restrained. * P (Cardiac output, CO) < 0.05 a/d converter performs a/placebo of each group. † P a/d converter performs a/< 0.05 Veh I/R (n=4-6 group). Also 6b: DHE dyeing of cardiac muscle cells for confocal microscope Image. (DAPI: DHE/DAPI/blue: pink ) 6c also: inflammatory of the marker mRNA the expression the representative Image (MCP-1 and TNF-α). 18S mRNA expression is been used as internal control (internal control). Also 6d: after damage I/R, caspase-3 BRAP upon administration of active assay. * P < 0.05 a/d converter performs a/placebo of each group. † P a/d converter performs a/< 0.05 Veh I/R (n=4-6 group). Also 6e: TUNEL of cardiac muscle cells for dyeing exemplary result confocal microscopy. Also 6f: TUNEL positive reaction of quantifying cells/total cardiac muscle cells. * P < 0.05 placebo of each group. † P a/d converter performs a/< 0.05 Veh I/R (n=3-4 group). DHE dyeing, determining expression of an mRNA, caspase active assay, and TUNEL analysis after damage I/R surface of the heart in heart tissue 24 so that it is not time.) Also the 7 7 (also 7a-7c) after administration of daily for at, either intraperitoneally, BRAP (1.5 mg/kg/day) Image and safety profile of set of histograms is formed inside the tie. as illustrated at. (Also 7a-7b: after administering BRAP daily, Creatinine to 7 (also 7a) and ALT (also 7b) level. Also 7c: after administration daily BRAP 7 to other organ tissue slices dyeing H/E representative (section) (n=4/group)). Also 8 (also 8a-8b) human embryonic kidney (HEK293) cells (also 8a) and mouse (also 8b) (NIH 3T3) fibroblast embryonic day [...] between BRAP rated by the MTT in a biocompatible of set of histograms is formed inside the tie. as illustrated at. LPS (1 μg/mL) also Figure 9 shows a of the mouse and is activated by generation of ROS in embryonic fibroblast (NIH 3T3), which display inhibitory effects on. timing the communication with. Also after damage the I/R 10 (also 10a-10c), framework the brain while decreasing, and treatment BRAP (Stroke wok, SW) (also 10a), (10b also) pak the coefficient which it will dance (ejection fraction, EF), (fractional shortening, FS) and partitioning shortened rate (also 10c) is formed inside the tie. as illustrated at graph a bar. Also the I/R 11 (also 11a-11b) after damage, TNF-α and treatment BRAP MCP-1 (also 11a) and (11b also) quantitative measurement of the expression of mRNA for is formed inside the tie. as illustrated at histograms. (* P < 0.05 a/d converter performs a/placebo of each group. † P a/d converter performs a/< 0.05 Veh I/R (n=4-6/group)). Also Figure 12 shows a 4 - (1, 3, 2- d jade company barley difficulty -2-one) phenyl methanol (4 - (1, 3, 2-dioxaborinan-2-yl) phenyl methanol) of H ' NMR spectrum and. timing synthesis. By also Figure 13 shows a 4 - (1, 3, 2-dioxaborinan-2-yl) phenyl methanol H2 O2. timing the communication with a bar erase. Experiment example, chemical said including WIPO intensity of the light emission (rubrene) (diphenyl oxalate solution) and diphenyl oxalate liquid been measured after the reaction. Boronate said (10 µm or 1 µm) the H2 O2 solution (10 µm) been added to. H2 O2 and a 1 then reactions, [...] liquid is H2 O2 has been added to the is, chemical the luminous intensity for recording/reproducing sound using a (luminometer, (Femtomaster FB12, Zylux Corporation, TN, US)) been be measured by use of. Figure 14 shows a (on) and also elongated, various BRAP dose the oral after reperfusion for 24 (creatinine) creatinine time level timing histograms includes (below). After reperfusion also Figure 15 shows a, 24 time marker inflammatory MCP-1 and TNF-α is a timing images. After I/R also Figure 16 shows a, DHE is images timing dyeing. The DAPI which appear is red and the dyeing DHE, a blue. made visible. Figure 17 shows a also after I/R TUNEL is images timing dyeing. TUNEL the green in which the, .made visible, a blue the DAPI. The present invention refers to 4 - (hydroxymethyl) phenyl at step Nick ester (4 - (hydroxymethyl) phenylboronic ester) (boronic esters) such as a boropeptide new been discovered and undesirable of nick S relates.. According to a embodiment, the (boronic esters) nick S boronate said of the present invention 4 - (5 - (hydroxymethyl (- 1, 3, 2-methyl-5-one-2- d jade company barley difficulty ) phenyl methanol (4 - (5 - (hydroxymethyl) - 5-methyl-1, 3, 2-dioxaborinan-2-yl) phenyl methanol, BRAP) includes. According to another embodiment, of the present invention the (boronic esters) nick S boronate H2 O2 the reacts with 4-hydroxy benzyl alcohol (4-hydroxybenxzyl alcohol, HBA) to form a. The present invention refers to in addition, of the present invention including a nick S compositions for the boronate (boronic esters). According to a embodiment, of the present invention compound and/or the composition (Acute Coronary Syndrome) acute coronary syndrome, ischemia between, elongation at ischemia, ischemia of the brain, coronary artery disease, thromboembolic of and/or vascular right circuit alcoholic beverage resuscitation associated with ischemia/reperfusion injury including oxide related disorders useful in treating and/or preventing the. H2 O2, such as oxidative stress the production of and of, causing ischemia/reperfusion (I/R) damage is mainly caused by to developing. Therefore H2 O2 inhibition of stress oxide I/R. very important for the treatment of damage. Of the present invention compounds are H2 O2 is prodrugs antioxidant activated, a process for specifically preparing, such as oxidative stress site which may be targeted, killing activity-cell anti-inflammatory and can be exerted. As described to the present invention, for producing phenol (bioactive) bioactive the present invention refers to H2 O2-can be removed (phenylboronic ester) provides nick S phenyl boronate. nick S boronate (boronic esters) of the present invention the H2 O2 excellent specific reaction, which is nontoxic.. Also 1a, such as a be schematized to, H2O2 using HBA that is activated by drug bulb boride antioxidant (H2O2-activable, anti-oxidant boronated prodrug) in BRAP was combined. Any limited by theory is not limited, a boropeptide BRAP nick S (boronic esters) compound, such as a minimum two of beneficial therapeutic activity.. In terms of one, the rapid BRAP a high specific high level of H2 O2 is oxidized and by, -charge signal followed by a H2 O2 mediated oxidative stress and. to limit damage. Another aspect in, H2 O2 mediated boronate HBA generates a glass oxide nitrate, oxidative stress tissue same in endogenous antioxidant is to exert and antiinflammatory activity. In other words, compounds of the present invention said H2 O2 antioxidant and anti treating inflammation by etching are removed and then and emit material. H2 O2 that is activated by the present invention refers to for providing BRAP H2 O2 only when produced and is H2 O2 for effectively setting the level of and to lower, normal physiological state a generally entails H2 O2., avoiding inhibitors. As such, harmful strategies targeted of the present invention said high H2 O2 is effective to reduce concentration of undesirable potential adverse effect in addition a limited. Defined (Definitions) If there is no defined separately, used in the present invention of all technical scientific terms does not generally such as those understood by photopolymerization initiator represented by chemical. In the present invention are of the following reference literature written many terms provides definition is capable of being isolated from: Singleton et al. , Dictionary of Microbiology and Molecular Biology (2nd ed.1994); The Cambridge Dictionary of Science and Technology (Walker ed. , 1988); The Glossary of Genetic, 5th Ed. , R. Rieger et al. (Eds), Spriner Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). Generally, wherein said used pharmaceutical artworking method designated, empirically chemistry and polymer organic chemical does not process typically used in is one known well. Described to the present invention, that does not term "about (about)", vibration such as ultrasonic vibration is in the cells in will can be understood by that is used which may vary from some extent feed off in for may be 2000. Amount, and duration measures such as b when he mentioned the value it (about) about terms used in the present invention the method is suitable for performing a specific meter portion ± 20% or ± 10%, more preferably ± 5%, more preferably ± 1%, still more preferably ± 0.1% including means the degree of range. Used in the present invention, said terms "administration (administration)" method by any suitable provided to a subject composition of the present invention said.. Used in the present invention, said terms "BRAP" the 4 - (5-hydroxymethyl) - 1, 3, 2-methyl-5-one-2- d jade company barley difficulty ) phenyl methanol) (4 - (5 - (hydroxymethyl) - 5-methyl-1, 3, 2-dioxaborinan-2-yl) phenyl methanol) blades, presenting a. Used in the present invention, said terms "CPB" surgical exhibits right circuit alcoholic beverage resuscitation. Used in the present invention, said terms "CABG" exhibits keratoplasty diversions coronary artery the operation. Used in the present invention, said terms "composition (composition)" or pharmaceutical composition (pharmaceutical composition " pharmaceutically a carrier having capacitors useful in the present invention at least one composition exhibits mixture of. Said pharmaceutical composition, to a subject facilitating the administration of said composition. Used in the present invention, the dichloro [...] said terms "DCF" (dichlorodihydrofluorescein] blades, presenting a. Used in the present invention, the terms "DCFH-DA" denaturant antibiotic non- [...] exhibits and (dichlorofluorescein-diacetate). "Bottle (disease)" cell as by, normal tissues or organs a or interference material coated with. mixture by the addition of an initiator conditions or disorders. Ischemia of the brain structure of a examples, surface of the heart ischemia, retinal of ischemia, ischemic colitis, severe it does not do ischemic, ischemic acute renal failure, stroke, brain trauma, fetal [...], ischemic/reperfusion injury or ischemic/reperfusion injury includes for treating or preventing ischemic diseases such as complications. Ischemic/reperfusion injury (CPB) right circuit alcoholic beverage resuscitation can be also associated, of adherent component diversions a coronary has said CPB (CABG); valve, recovery or aneurysms or deficiency; heart and/or lung transplantation of; waste thrombus keratectomy; or waste thrombotic endarterectomy discectomy, in addition to this, atrial fibrillation, infarction (infarct extension) such as on a lateral side of the guide (or CABG) surgical associated with CPB, infarction associated artery occlusion material (reocclusion of an infarct-related artery, IRA), circulation infarction (recurrent infarction), arrhythmia, stroke, increased, pears, pineapples, jujubes, severe road (small-to-moderate myocardial infarction), ventricular tachycardia /fibrillation associated with failure congestive and (ventricular tachycardia/fibrillation) ischemic/reperfusion injury includes complications. Compositions of the present invention in addition solid organ transplant (liver, elongated, such as waste or a cardiac) for including reducing ischemic damage of tissue implanted to, protection for increasing efficiency of client-server or solid (liver, elongated, such as waste or a cardiac) 2000. According to of the present invention in the embodiment, of the present invention method are (Acute Coronary Syndrome) acute coronary syndromes, ischemia between, elongation at ischemia, ischemia of the brain, coronary artery disease, resuscitation of and/or vascular right circuit alcoholic beverage thromboembolic associated with. useful for ischemic/reperfusion injury. Used in the present invention, said terms "DMSO" exhibits and (dimethyl sulfoxide) sulfoxide, R2 may be dimethylamino. Used in the present invention, said terms "DOX" the doxorubicin (doxorubicin) exhibits or salt. "By an amount effective" email widow, a web page or, as compared to subjects not treated of the bottle so required to ameliorate the amount by the which.. Treatment of diseases for treatment, without limitation, are activated for carrying out the present invention of an amount effective the regimens, age, weight general. various according to health in a subject. Ultimately, dentist and reflected to the second veterinarian use drug delivery and in an amount appropriate will determine an is (Dosage regimen). The amount said "effective" amount as the free surfaces. Used in the present invention, said terms "HBA" the 4-hydroxy benzyl alcohol (4-hydroxybenzyl alcohol) or a salt or solvate derivative blades, presenting a. Used in the present invention, an inductive has iNOS said terms and presents a nitric oxide synthase (inducible nitric oxide synthase). Used in the present invention, the "(Instructional material) data for education" utility composition of the present invention that can be used to deliver the Publication, recording, drawing or any other representing medium includes. In one example, the (Instructional material) data for education said compound or composition of the present invention useful when administered kits useful for. may specifically be part of a peer. Said data for education kit, for instance, (Instructional material), containing that compound or composition of the present invention to a vessel which may be attached or composition a container can be and moved with the. Relatively, the (Instructional material) data for education said recipient the educational data and compositions the cooperate to from a container dropping it may be moved. For example, said (Instructional material) data for education is for use in the kit and, said or for hand for of using the vaccine and pharmaceutical compositions said formulations of composition is for hand for use. Used in the present invention, "I/R" has ischemic/reperfusion (ischemic/reperfusion) exhibits and. Used in the present invention, the lipid polysaccharide "LPS" blades, presenting a (lipopolysaccharide). Used in the present invention, "MCP-1" for mononuclear cell chemotaxis, blades, presenting a -1 (Monocyte chemotactic protein-1) protein. Used in the present invention, " microparticles (Microparticle) in about 10 nm in the range of about 1,000 µm exhibits and has an average diameter of particles. According to a embodiment, the mean average diameter of the is in the range of about 100 nm in 100 µm. According to another embodiment, the mean average diameter of the 10 µm in is in the range of about 100 nm. According to another embodiment, the mean average diameter of the 1 µm is in the range of about 200 nm in. According to another embodiment, about 200 nm in the mean average diameter of the is in the range of 800 nm. According to another embodiment, about 500 nm is the mean average diameter of the. According to another embodiment, said. close to substantially spherical particles. Used in the present invention, the 3 - (4,5-dimethylthiazol-2-yl) - 2,5-diphenyl tetrazolium bromide exhibits and "MTT". Used in the present invention, said terms "OVA" and presents a the of albumin (ovalbumin). , Such as oxidative stress due to damage a, activated oxygen species associated with. cell damage. Used in the present invention, "PCL" the poly (ε-caprolactone) exhibits or a salt thereof. Used in the present invention, "PGA" exhibits the poly (glycolic acid) or a salt thereof. Used in the present invention, the "pharmaceutically acceptable" or compounds useful in the present invention without removing the biological activity, such as a dilution or a carrier exhibits material, relatively toxic, i.e. said material the undesirable vibrational non biological effects any compounds is bound or contained harmful interaction of the elements is not. Used in the present invention, "PLA" exhibits the poly (lactic acid) or a salt thereof. Used in the present invention, said terms "PLGA" exhibits the poly (lactic-co-glycolic acid) or a salt thereof. "(Prevent). preventing", "(preventing) preventing" or "prevention (prevention)" used pharmaceutical compositions, single unit dosage forms agonists or as at the beginning of the symptoms associated with diseases or health status therapeutically does not occur in a subject said diseases or health status beginning of symptoms associated with circulation promoted. to avoid or delay. Diseases, health conditions and disorders are wherein exchange to employ one having an. "The control group (reference)" is conditions control standard or rotation. Used in the present invention, the active oxygen kind"ROS" blades, presenting a (reactive oxygen species). The ROS including oxygen electrochemically-activated molecules and oxygen ions, includes (peroxide) superoxide (superoxide) and peroxide. Used in the present invention, the physical treatment "reaction conditions", chemical agent exhibits or a combination thereof, for transmitted, the to promote a reaction required to is required or elected. For reaction conditions without limiting electromagnet are an exemplary radiation, heat, catalyst, chemical agent (for example, however limiting free acid (acid), base (base), electrophile (electrophile), (nucleophile) electronic nucleophile) and buffer is (buffer). Used in the present invention, "salt" an inorganic, organic acid, inorganic base, organic base, solvates, hydrate, or their clathrate (clathrates) for including, in the present invention exhibits well as salts of the compound of that are in consideration. Used in the present invention, said terms "salt" in the present invention the interior of an internal combustion engine therewith is free acid encompasses addition salt of a base or glass. Compatible acid additional salt can be produced from inorganic or organic acid. Examples of mineral acids hydrogen chloride acid, hydrobromic acid, hydrogen iodide acid, nitric acid, carbonate, sulfate, phosphate, perchlorate, includes (tetrafluoroboronic acid) acid [...] and tetrahydrofuran. Suitable aliphatic organic acid has a predetermined, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic grade may be selected from an organic acid, for example formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, bezenesulfonic, patothenic, trifluoromethanesulfonic, 2-hydroxyethanesulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, β-hydroxybutyric, salicylic, galactaric and includes galacturonic acid. In the present invention additional a suitable base of a semiconductor device using such a for example salt, lithium, calcium, magnesium, potassium, ammonium, sodium, zinc such as alkali metal, alkaline earth metal and includes (metallic salt) metal salt including transition metal salt or the like. Acceptable base additions for example in addition salt, N, N '-dibezenylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, such as procaine and meglumine (N-methyl-glucamine) made basic amine (basic amine) includes organic salt. For example, salt all compatible acid or a base, that corresponding free base by reacting the prior art are emitted from said corresponding a glass base compound made of the method. Used in the present invention, "subject (subject)", "patient (patient)" or "personal (individual)" the human or non-human mammals or sail may. Mammalian non human positive for example, bovine, horse, porcine, two, cats and mouse (murine mammals) foods and animal feed such as mammalian with includes a PET. Preferably said subject is human. Used in the present invention, the terms "THF" said blades, presenting a tetrahydrofuran. Used in the present invention, said terms "TNF-α" has tumor necrosis factor alpha (Tumor necrosis factor-alpha) exhibits and. "(Treat). treating" and "(treating) treating" and "treatment (treatment)" in the present invention the active material to a subject by administering a compound or subject diseases or according to the input orders by a health status of symptoms whose significance is the and frequently exhibits constant so. Used in the present invention, the "TUNEL" blades, presenting a terminal deoxynucleotidyl transferase dUTP nick end labeling. Used in the present invention, "pharmaceutically acceptable salts" an inorganic, mineral base, organic acid, organic base, solvates, hydrate, including and their containing inclusion compound is pharmaceutically acceptable for a non-toxic acids and bases that are produced from exhibits well as salts of the compound of administered. Through the present specification, the present invention to perform various one side with a formal been presented in within range. The present description of the invention in fractional form range been described for object includes a person and compact, interpreted in a limited manner range of the present invention is that air is not subject to should understood. Therefore, said range of description, the level of within range for partially suitable when integer in the range and number of individual for disclosure specifically both range observed the at. have to be considered. For example, in 1 1 varies from 6 up of description 3 in, 4 in 1 until, until 5 in 1, in 2 until 4, until 6 in 2, in 3 such as until 6 lower range and for example, such as in a range 1, 2, 2.7, 3, 4, 5, 5.3 and 6 specifically disclosure number of individual observed the at. have to be considered. This 2000 regardless the width of a range. , Such as oxidative stress , Such as oxidative stress damage due to the, antioxidant defense in reduction and simultaneously oxygen species take place increases as the of generating, signs of active eventually oxygen kind (ROS) is induced. This cell defense system and then return to that segment with, overriding normal eventually worn damage to cell functioning can be is LED to death. (I.e., spontaneous cell death (apoptotic cell death)) In particular, ischemia/reperfusion (I/R) produced during, fgfr5, forms of ROS in H2 O2 the, inflammatory cytokine precursor release and/ self-destruction company cells play a significant role, by deriving a further and more increase to tissue damage. H2 O2 in addition the hydroxyl radical, hypochlorite and lung rock new Oh nitric acid saltit buys the salt and ROS toxicity other high such as bulb material that has. H2 O2 oxidative stress and associated with accumulation of inflammatory reaction is like damage (I/R) reperfusion-ischemia a variety of above-mentioned conditions the incidence and of intervention in disease progression layer coding means, relates closely (development). I/R damage (Acute Coronary Syndrome) acute coronary syndrome, stroke ischemia elongation at and is, such as thromboembolic and vascular right circuit alcoholic beverage resuscitation variety of clinical. viewed at to provide improved strength. A reperfusion of blood flow in the ischemic tissue H2 O2 induces production of room and allowing a large number of, , such as oxidative stress and the cell causes the damage, the highest frequency to further tissue damage. Ischemic diseases degree of of tissue damage and pathological conditions associated with the most important for death since the factor, these conditions can be inhibited from death of cells in a positive processing results is one approach is more important for is. Exceeds a capabilities anti-oxidation portion using an excessive amount of H2 O2 the oxidative damage and decides the sensitivity to. Therefore H2 O2 for the production of partially concentrated on the pathology in a variety of disorders, such as oxidative stress damage may stop a therapeutic induction of a therapeutically adequate is method. However human clinical research for treatment antioxidant generally in a beneficial result in the came disappointed the effects. Lack of benefit these clinical setting, the subject matter of the reason one of non specific manner, inhibitors of ROS is and with respect to the fact that is undesired. Although during damage I/R, H2 O2 (in micro range) overproduction of even is detrimental, extremely low levels of H2 O2 (in nanomolar) physiological normal a cell-cell functioning for signal. that is required to. 2011 years, substantially 11% adult Americans popular, a cardiovascular disease in a patient sample, at least 50% thereof, such as stroke, hypertension and in addition will experience complications. Although various cardiovascular disorders having the etiology bottle (atherosclerosis) and induction of the initial onset of atherosclerosis, heart until carrying a blood supply from and the heart for nascent blood vessels is (occlusion of primary vessels). Bottle signal according to progress of the, right circuit alcoholic beverage resuscitation (CABG) or coronary artery (CPB), such diversions of adherent component to provide the requisite result in clogging artery, will continuously, thereby improved are new vasculature to plaque already passing through the spraying container where the blind creating or bypass to bypass the is. Substantially 2% by the 395,000 or adult Americans, such as life-threatening heart diseases to ROS without having to go through an is request year process is CABG. CABG is requested by the reaction with the expansion driving pathogen long post-surgical ischemia or reperfusion little complications associated with an apparatus for detecting a motion which would have resulted if is a surgical procedures for. During CABG (individual % generating degree) oxidative associated with alveolar damage the complication, but not limited, atrial fibrillation (until 40%), infarction on a lateral side of the guide: containment material artery relevance-infarction (IRA) (5-30%), circulation infarction (17-25%), arrhythmia (13.6%), reduced renal function (5-10%), stroke (6.1%), a mi (small-to-moderate mi) (2-4%) severe to developments to the so-, intracardially palpitation /fibrillation (2-3%), congestive failure (88 80001040888%), GI dysfunction (2.3%) and acute elongated deficiency diseases (0.7%) includes. In particular ischemia and reperfusion impairment to, substantially 15% of these the developing complications before and after a surgical patients, per patient 1,0000 is additional expense of dollars. Addition to element deterioration to damage, major surgical CABG according to at least one of the metal mechanism of pathologies subsequent I/R is damage, such as containment of IRA can be valves are. Approximately 5-30% patient undergo a hole on a lateral side of the infarction are 17-25% IRA are initially patient experience a substantially. I/R that experienced the patients, fastening Stirling vascular fine myocardium and in addition combined with arrhythmia (stunning) (13.6%), and initial damage frequently objects, people, Letters and the difficult bleeding (5.6%) for including clinically with at least one alpha c antigen may be present. Furthermore, I/R of Saga-as a result of myocardial necrosis at this moment, the CPB plurality of to a result can know a response presence to patients. Of the present invention said antioxidant compound (for example, 4 - (hydroxymethyl) phenylboronic ester) is generally (I/R) reperfusion-failure and ischemia oxygen kind active associated with alveolar damage treatment and/or prevention of diseases and disorders useful. In any in the embodiment, therapeutic activity of compounds of the present invention said time and space-effective preferred conditions provides switch for sensing a voltage of the pharmaceutical. In another in the embodiment, of the present invention said compound to the target area with stimulating which sensitive, this said compound enhancing the and, at the same time, reduces the undesirable side effects. Although most of ROS survive although prevented from becoming extremely way, during the writing into the, H2 O2 a production is stable highest ROS. Consequently, H2 O2 from oxidative stress concentration of high levels during tend accumulates. and without causing damage cells. Only H2 O2 which reacts with the ability of BRAP, as seen during damage I/R, produced and in of pathological H2 O2-activated do not suffer a part at ingredients outputs a relay driving signal.. Gastrodia elata BLUME (gastrodia elata) includes an additive principle active ingredient of the HBA, brain and coronary ischemic injury protective against neurogenerative diseases and serves to direct. In any in the embodiment, the BRAP H2 O2-that is activated by drugs in bulb HBA, wherein H2 O2-in in biological systems composite oxidation boronate mediated H2 O2 and reacts with H2 O2 access selective chemical to remove. act as. Boronate (Self-immolative) a apoptosis burning to deathnick S BRAP (protecting group) protector (boronic esters) with the quickly H2 O2 by etching are removed and then, and emit a therapeutic HBA. Any theory is defined by cutting without damaging the back page, these properties are BRAP method targeted is oxidized in tissues suffering from stress the synergistic antioxidant and antiinflammatory shows an ornamenting effect by being a. Furthermore, resulting from an association (boronic esters) boronate (Masking) of masking HBA nick S in addition the biocompatible same and makes change before the solubility to water, a pharmaceutical wider allows the applicability. As described in the present invention, stable acid has BRAP unit moves simultaneously at the same distance, this about orally bioavailable. the as information. As described in the present invention, and of mouse I/R surface of the heart through the use of model damage, reduced effective has BRAP, such as oxidative stress, inflammatory response, and copyright 2001 disclosure apoptosis. In addition 7 administration of a high concentration of daily between BRAP between or an elongated implying shows no dysfunction, excellent in addition tissue analysis connection structure is a structural safety profile. Such BRAP after the effects of the available resources in a reduced long term damage results of function improvement. cause. As such, H2 O2-BRAP that is activated by the, I/R damage to is a very potent targeted therapeutic material that has. In any in the embodiment, . dissolved in compounds of the present invention said. In another in the embodiment, of the present invention said mixture in an aqueous medium to. are hardly soluble unpredictable, or break down. In any in the embodiment, of the present invention said compounds includes microparticles. In another in the embodiment, which is nontoxic a microparticles of the present invention and preferably biocompatible, physiological under conditions decomposition permits. In another in the embodiment, of the present invention said microparticles a poly lactic (PLA), poly (glycolic acid) (PGA, poly (lactic-co-glycolic acid) (PLGA), and poly (ε-caprolactone) (PCL) includes or mixtures thereof. Antioxidant of the present invention of the present invention said micro particles and/or anti-inflammatory compound and/or composition useful emit or. Description of the invention The present invention refers to-inflammatory and/or antioxidant form an intermetallic compound the engine for capable of partially reacted least coagent said nick S boronate includes (boronic esters). In one in the embodiment, the (boronic esters) boronate said nick Sat step Nick 4 - (hydroxymethyl) phenyl ester (4 - (hydroxymethyl) phenylboronic ester) includes. In other in the embodiment, said-inflammatory and/or antioxidant compound phenol system compound. In another in the embodiment, said phenolic compounds are 4-hydroxy benzyl alcohol (4-hydroxybenxzyl alcohol, HBA) includes. Boronate said nick Snick it buys boronate alcohol and the (boronic esters) includes (boronic acid), said a boropeptide nick Snick it buys boronate (boronic acid) and alcohol (boronic esters) covalently to form a constitution: this level shifter circuit. In one in the embodiment, the aromatic is nick it buys Wibro said (boronic acid). nick it buys Wibro said other in the embodiment in the (boronic acid) 4 - (hydroxymethyl) phenyl nick it buys at step (4 - (hydroxymethyl) phenylboronic acid) includes. In other in the embodiment, said alcohol (diol) diol, triol (triol), tetra ol (tetraol), pen towel (pentaol), hexa ol is polyol (polyol) is adapted to produce an upper or more (hexaol). In other in the embodiment, said alcohol is triol or diol. Any other of the in the embodiment in, the diol (diol) 1,3-propanediol (1,3-propanediol) includes. In another in the embodiment, said BRAP nick S boronate includes the (boronic esters). In another in the embodiment, the triol (triol) - 2-methyl propanamide 2 - (hydroxymethyl) - 1,3-diol (2 - (hydroxymethyl) - 2-methylpropane-1,3-diol) includes. In another in the embodiment, said nick S it shakes off boronate (4 - (1, 3, 2-2- d jade company barley difficulty ) phenyl) methanol ((4 - (1, 3, 2-dioxaborinan-2-yl) phenyl) methanol) includes. In another in the embodiment, said acid and alcohol are subject is a non-toxic biocompatible properties and has. In another in the embodiment, said subject is a mammal. In any in the embodiment, the tetrahydrofuran (tetrahydrofuran) said nick S boronate (boronic esters), dichloro methane (dichloromethane) or dimethyl formamide (nonaqueous solvent) amide (dimethylformamide) in alcohol and said non-aqueous solvent such as Wibro nick it buys by conflict the contact (boronic acid) can be produced. nick S a manufacturing (boronic esters) the extraction, crystallization, precipitation, chromatography such as, but without limit to an, in the surveillance industry per using a well-known method can be purified. In one in the embodiment, nick S boronate (boronic esters) represents a pharmaceutically composition of the present invention is part. In one in the embodiment, microparticles has nick S boronate (boronic esters) of the present invention included. In another in the embodiment, said microparticles includes at least one polymer (polymer). In another in the embodiment, said polymer (polymer) the poly lactic (PLA), poly (glycolic acid) (PGA), poly (lactic-co-glycolic acid) (PLGA), and poly (ε-caprolactone) (PCL), and associated selected from the group consisting of the free surfaces. In another in the embodiment includes liposomes that are said micro particles. In another in the embodiment, is nontoxic and said micro particles biocompatible, physical conditions and may degrade in-anti-oxidant and anti-while HBA clause inflammation, such as for anti-inflammatory and/or antioxidant compound and emit. Microparticles of the present invention an antioxidant or anti-inflammatory composition useful as and drug delivery systems components. In one in the embodiment, said microparticles about 20 µm color has diameter of about 200 nm to assure proper amount. In another in the embodiment, microparticles color has diameter of about 200 nm to about 800 nm to assure proper amount. In another in the embodiment, microparticles color has diameter of about 400 nm to about 600 nm to assure proper amount. The present invention refers to in addition and/or anti-inflammatory antioxidant further includes the pharmaceutical composition, said composition comprising active as an element of the present invention includes nick S boronate (boronic esters). The present invention refers to in addition, for the prevention or treatment of ischemic diseases, which contain these a pharmaceutical composition, said composition comprising active as an element of the present invention includes nick S boronate (boronic esters). In the present invention that are in consideration not limited a against ischemic diseases examples of the brain ischemia, surface of the heart ischemia, diabetic cardiovascular disorders, heart failure, myocardial hypertrophy, retinal ischemia, ischemic colitis, severe it does not do ischemic, ischemic acute renal failure, stroke, brain trauma, fetal [...], glaucoma, diabetic neuropathy, ischemic/reperfusion injury or ischemic/reperfusion injury complications, and acute sentimental branch lifestylere-tube /ischemic systemic such as (cardiac arrest resuscitation) includes type. In one in the embodiment, said ischemic/reperfusion injury right circuit alcoholic beverage resuscitation is associated (CPB) is connected to the semiconductor layer.. In another in the embodiment, ischemic damage associated (CABG) coronary artery bypass of adherent component is connected to the semiconductor layer.; valve, damage or aneurysm recovery; heart, waste, elongated, and/or is pancreatic implant; waste thromboembolic; endometrial removing or waste thrombotic. One in the embodiment in, CPB are compounds of the present invention (and/or CABG) surgical (i.e., atrial fibrillation, infarction on a lateral side of the guide, infarction associated artery material occlusion (IRA), recurrence infarction, arrhythmia, renal function reduced, stroke, severe to developments to the so-a mi, ventricular tachycardia /fibrillation, decongestion heart failure, renal and acute dysfunction GI) useful for the treatment of complications associated with. The present invention refers to in addition solid organ transplant (liver, elongated, such as waste or a cardiac) long-term preservation or solid (liver, elongated, such as waste or a cardiac) associated with for the treatment or prevention of ischaemic damage pharmaceutical composition, said composition comprising active as an element of the present invention includes (boronic esters) nick S boronate. Efficacy antioxidant pharmaceutical compositions of the present invention, clause inflammation effect, in preventing or treating ischemic damage or for having to at least one known active elements are may include. Organ or tissue transplantation The present invention refers to organ or tissue transplantation for enhanced method characterized in that. Ischemic damage and reperfusion damage implantable cells, tissue, or organs. the reduction of the rate of survival of. The present invention refers to this damage capable of reducing composition comprising a. Preferably, composition of the present invention is not limited, and transplant before and after implant during heart tissue, heart, kidney tissue elongated, hypercholesterolemia tissue, liver, waste tissue, waste, the pancreatic tissue, pancreatic, small intestine tissue, small intestine, Thymus, bone, cartilage, muscle tissue, tendon, cornea, epithelial tissues, skin, heart valve, neurons, neural, endothelial tissue, artery, or veins including tissues or organs (organ or tissue (donor) donation) is administered in to. Sugar method for organ transplants is well known to where a new file does not exist. Interchangeable collapsible plug In terms of one, the present invention refers to a host in need thereof associated with oxygen kind or activity inflammation in a subject, to prevent or treat disorders includes a method. In one in the embodiment, of the present invention the method (boronic esters) nick S boronate quantities, effective treatment of treatment includes administering to the subject a, said ester (esters) in the subject received in a body-inflammatory and/or antioxidant compound to emit least partially undergoes a decomposition. In another aspect, the present invention refers to a subject oxygen kind active in at least one body part or inhibiting prevents the formation of (ROS) includes method, of the present invention the method (boronic esters) nick S boronate quantities, effective treatment of treatment includes administering to the subject a, said ester (esters) in the subject received in a body-inflammatory and/or antioxidant compound emission an at least partially is material undergoes a decomposition, thus subject in ROS for forming at least one body part is or inhibiting is prevented. In another aspect, the present invention refers to in tissues or organs for transplantation ischemic damage or reperfusion injury includes method for reducing, said method contains an implantable nick S boronate of the present invention during or after implantation of tissues or organs and a (boronic esters) which contact, said ester (esters) has anti-inflammatory and/or antioxidant compounds for it to emit least partially is material undergoes a decomposition, damage or ischemic organs, or organized according copyright 2000 reperfusion injury. Formulations/administration Pharmaceutically acceptable composition of the present invention a carrier (carrier), excipient and/or number can include a dilution liquid, suitable to a subject method. can be administered. Per composition of the present invention normally by methods well known in industry according to method, a or sterilization oral dosage form including solution injectable in various forms can be produced. In addition to this, said composition from shutdown may be used as a delivery system. In one in the embodiment, the composition of the present invention can be produced to nanopowder. Said composition powder, granules, purification (tablets), capsule, suspension (suspension), emulsion, syrup, aerosol, a formulation for external, suppository, injectable solution to a sterilized can be produced. Suitable well known to industry per for example dosage forms, Remington ' is unknown to s pharmaceutical science (Mack publishing Company, Easton Pa).. Of the present invention may be included within the composition a carrier, a dilution and number excipient lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidione, water, methylhydroxybenzoate, talc, propyl hydroxylbenzoate, includes mineral oil or magnesium stearate. Number (filler) filling composition of the present invention, extender number (extender), binder, wetting, disintegrating agents (disintegrants) or surfactant of the commonly used such as excipients or dilution can be produced. Purified formulations that are solid for parenteral administration, bolus (pills), powder, granule or capsules containing a and, the formulations that are solid the, addition to compositions in addition, at least one number excipients, for example, starch, calcium carbonate, sucrose (sucrose) initiated, gum or gelatin (lactose) lactose includes (gelatin). Single vehicle addition to, magnesium [...] or talc and a lubricant, such as can be used in addition. For parenteral administration the suspension liquid (suspension), solution, emulsion (emulsion) includes, and a syrup, various number excipients, for example, wetting, aromatic (flavoring agents), perfume (aromatics) may include and a preservative, addition single dilution liquid specific data are frequently the water which is used and a liquid paraffin may include a. For parenteral administration (sterilized aqueous solutions) coating it with an aqueous solution, a sterilizing formulations, (non-aqueous solutions) nonaqueous solution, suspension (suspension), emulsion (emulsion), includes eye drops, suppository, and the freeze-dried preparation. Non-aqueous solvent or suspension agent (non-aqueous solvents) (suspending agents), propylene glycol (propylene glycol), polyethylene glycol (polyethylene glycol), olive, such as an oil (ethyl oleate) such as vegetable oil or ethyl oleic injectable ester (esters) may be used. As the base of suppository, witepsol, Macrogol, Tween61, cacao butter, laurin fat, or glycerogelatin can be is used. Dose has a preferred pharmaceutical composition of the present invention, base lines of patients' conditions and body weight, type of bottle, about form of, route, , and differ depending on the dosing period, suitably by one skilled in the art can be selected. For a favourable effect, of the present invention said pharmaceutical composition can be dosage in kg/day/0.01-100mg. Said composition over several times or once per day can be administration. The various pathway composition of the present invention treated by can be administered to a subject. Conclusion of the administration of all for example, parenterally, rectally, or intravenous, intramuscular, avoid, dermis, intrauterine, ventricle or epidural the free surfaces is taken into account in such as injection. Other pointing if there is, the description and claims and an amount of raw materials to be used, molecular weight, such as reaction conditions representing properties, such as all numbers the term 'about (about)' invention, every in cases in is modified to. can be understood. Therefore, if not to be directed opposite, a and appends the description to be a numerical variable said claim, a method for determining the desired be obtained in the present invention receives the laser light source device, which can be various is approximation. At least, defined application of principle equal in addition the following is claimed an attempt rather than as, each a numerical variable a general rounding (rounding) technique reported by applying a number of numbers and important considering should being interpreted with. That describes a range broad of the present invention a numerical ranges and parameters are in spite of the approximation, as set out in the embodiment detailed as possible metrics said. reported of exactly one. Any metrics, however, their each trial measuring essentially standard deviations found in a a as a result, one of error includes essentially (Errors). In the present invention is provided and range value which is less constructed in an active matrix displaying device, all the values including ranges value and the ranges of the present invention means that contained within range it should understood. Furthermore, all values included in is within range range of value with more higher or lower threshold in addition by applications, present also in addition the free surfaces taken into account. A one skilled in the art said embodiment therefore, the process described the present invention, embodiment examples, claims and example with a numerical equivalent a generally experiment and recognizing are no longer required or enough. Such equivalent are within range of the present invention consider the device to be in port located in the, appended to the present invention may be included by a claim. For example, longer is capable of being isolated from without the use of the experiments, reaction time, reaction size/amount, is experimentally such as and solvent is not limited to agent, catalyst, pressure, the large basis gun (, nitrogen standby), and oxidation/reductant by are, thus, the substitute of unknown and techniques including from fringe land reaction conditions within range of the present invention should be appreciated that will. In addition of the present invention are of the following in the embodiment described the side. However, a group consisting of carboxylate (teaching) a is described in the present invention by not limiting the has teaching or of the present invention disclosure (disclosure). In the embodiment The present invention refers to a reference to embodiment examples the free surfaces described herein. Is is provided to only the description embodiment examples, without limit to an embodiment is the present invention refers to examples, rather with the teachings provided in the present invention (teaching) result of certification as including all variable. Synthesis ofBRAP H2 O2-BRAP precursor antioxidant that is activated by the 4 - (hydroxymethyl) phenylboronic ester and a 2 - (hydroxymethyl) - 2-methylpropane-1, at room temperature for 3-diol been synthesis by reacting (also 1a). The white BRAP which obtained with water-soluble powder, its chemical structures1 H NMR been identified by (also 1b). Reaction of hydrogen peroxide and BRAP The BRAP H2 O2 HBA be used as a data carrier for undergoing abrupt metal insulator transition by to, 2 - (hydroxymethyl) - 2-methylpropane-1 and bornic acid, complementation designed to produce because 3-diol, H2 O2 BRAP of sensitivity for1 H NMR was illuminated with using. The BRAP H2 O2 including a D2 O added to, the changes to the signal portion is fixed on the monitor over time. H2 O2 in the presence of, the BRAP H2 O2 HBA be used as a data carrier quickly concentration dependent fashion for generating the n bit parallel data inputted, a novel aromatic proton peak 6.8 and 7.2 PPM sequences as signal produced by the. H2 O2 equivalent molar (equimolar) concentration (1 mm) in the presence of, the -5 minutes (boronic ester) nick S boronate most of hydrolysis half-life and removed into ingredient 30. Substantially all (boronic ester) group nick S boronate excess back 5 in 5 ingredient (5-fold excess) of H2 O2 (5 mm) removed by. However, H2 O2 the in the presence of secondary, Wibro said photonic ester (boronic ester) was remaining completely even after the 3. H2 O2 BRAP by using in addition UV apparatus for interfacing with the activity of the been the laboratory (spectroscopy). The BRAP H2 O2 been mixed, UV was monitor over time change in storage amount in the storage amount. 273 nm, HBA due to appearance of phenolic hydroxyl groups in at, improve over time, predicted Wibro photonic ester (boronic ester) has been demonstrated HBA cleavage of generation of. 90 minutes (also 2a) after the processing, the UV storage amount in BRAP further increase is visible have not been, their UV storage amount strength approximately HBA of the same concentration that was in the as. Without a limited by any theory, BRAP has of the same H2 O2 during (boronate oxidation) oxide boronate mediated H2 O2 removing can be. The probability is using (peroxalate chemiluminescence) chemiluminescent [...] was illuminated with. This excellent (peroxalate chemiluminescence) chemiluminescent [...] as exact bringing a molten raw material liquid into the convenience since the fluorescing molecules and H2 O2 a wide variety of chemical species including a for detecting tool for a variety of purposes (tool) been used as (Hadd, et al. , 1999, J. Chem. Educ. 76:1237; Lee, et al. , 2011, Bull. Korean Chem. Soc. 32:2187). Said pure H2 O2 very high solution using the emission strength (- 1.3x105 RLU). The addition of BRAP, in concentration dependent fashion, chemiluminescent strength and a significant reduction is force is outputted from (also 2b). Most of H2 O2 of the same concentration that was in the in the 1 ingredient BRAP been erased by a. In contrast, single group HBA (10 µm) did not reduce a chemical light emitting intensity. These observations are BRAP is H2 O2 the and are reactive with an organic acid and a H2 O2 are effectively removed to connection structure is a structural. Furthermore, the stability of the BRAP during incubation encoding while 72, affected by the ionic and/or acidic environment (pH 3.0) (also 2c) did not. Cytotoxicity ofBRAP At the time of initial cell toxicity experiment BRAP of in vitro (in vitro), various constant current source (cell lines) and adult RAT ventricular muscle cells (ventricular cardiomyocyte (ARVC)) 24 in a super large culture (primary culture) after incubation of time, such as 5 mm the significance of in a high concentration a cytotoxic and is not the certification. (Also 3a-3b and 8a-8b) In the embodiment 4. BRAP antioxidant characteristics Said BRAP antioxidant activity, LPS (lipopolysaccharide) stimulated by said optical (NIH/3T3) fibroblast and (RAW 264.7) macrophage of the mouse and using the test been (also 4a-4b). In cells stimulated creating a ROS cell in, H2 O2 hydroxy radical in various, such as by the action of oxidant and are fluorescent yellow-may be oxidized (dihydrodichlorofluorescein, DCF) [...] DCFH-DA (dihydrodichlorofluorescein-diacetate) a fluorescently fluorescent using been analyzed by (flow cytometry) (Kim, et al. , 2011, biomat. 32:3021; Cho, et al. , 2012, Adv. Funct. Mat 22:4038). Addition is not applied at a significant cells has no fluorescent DCF. Vice versa, to the reaction tower DCFH-DA is LPS DCF onto the phosphor groups induce the generation of ROS, a strong DCF exogenous the fluorescence revealed that in cells treated with (exogenous) LPS. The HBA of 0.5 mm in concentration dependent fashion, ROS generation using the inhibitory effect of moderate. However the BRAP of 0.25 mm, than HBA of 0.5 mm, to significantly different generation of ROS inductive LPS vibrationally stronger exhibit, which display inhibitory effects. ROS inductive LPS of similar inhibitors revealed that even fibroblast of a mouse (also 9). Cardiovascular disorders, such as oxidative stress associated with impaired and most general the problems associated with the clinically because the one, H2 O2 inductive cell death in cells from the effect of the BRAP protection, in been illuminated ARVC in addition in vitro. H2 O2 (25 mm) a relatively recessed part has a placing by etching the planarizing layer and the cell death, and of 30%. Said compared to the control group (vehicle control), a density dependent in BRAP, H2 O2 inductive cell death using the protection of the significance of from (also 4c). Effect of using a resuscitator quality monoxide BRAP Nitric oxide from oxidative stress of developing inflammatory neuropathy mainly caused by user is one by methods well known in proinflammatory (pro-inflammatory) is (mediator) mediator (Lundberg, et al. , 1997, Nature Medicine 3:30). In cells treated with LPS as no-for effect of BRAP (Griess reaction) reaction a parallel heat exchanger (colormetric assay) assay color based on using been the laboratory. A number of LPS inducing acid resuscitator quality monoxide in amounts the n bit parallel data inputted, , dose-dependent and generates a time BRAP as no-in (also 4d) exhibit display inhibitory effects on. Single family HBA in addition 0.5 mm a concentration above the only the n bit parallel data inputted suppressing non-resuscitator quality monoxide, this antioxidant better of BRAP. suggest that characteristics. BRAP anti-inflammatoryeffect LPS stimulated to BRAP anti-inflammatory effect in a cell, , iNOS (inducible nitric oxide synthases) TNF-α (tumor necrosis factor alpha) and level of inflammatory cytokines such as by measuring the been irradiation (also 4e-4f). The level of said TNF-α vibrationally significant subjecting the film to a treatment by LPS have been increased. The BRAP iNOS and TNF-α significantly both level of vibrationally by inhibiting the exhibit strong anti-inflammatory effect. HBA single group of only a higher capacity than in addition BRAP TNF-α been reduces the expression of, iNOS even higher capacity level of the enemy failed in their reduce the. The these observations with it was produced is BRAP H2 O2 of the furnace to eliminate number antioxidant simultaneously activated can act as mean negative. Furthermore, activity improved oxidation of said BRAP, H2 O2 mediated boronate (boronate) of oxidatively aftertreated, H2 O2-of erasing boronate, simultaneously produced and a (boronic ester) nick S HBA synergy effect is derived from at. BRAP extinction system cells of50,000 and ROS is BRAP to reduce the production cell death, and evaluates whether the inhibitors are an experiment using a computer to, base (hind-limb) I/R been performed in mouse model once the presence of a damaged. I/R [...] and [...] (ligation) ligation of the 1 time caused initially by [...] subsequently been by etching the planarizing layer and the perfusion of. The HBA or BRAP, reperfusion at the point of, either intraperitoneally (i. P) been administered to. I/R after damage of, histological analysis (histological analysis) the inflammatory cell increased penetration by connection structure is a structural damage between as certification (also 5a). I/R during, the HBA of liver injury in therapeutic efficacy a minimum but show, of such tissues BRAP doses of such as the well-being of significantly damage using the result. I/R during damage, BRAP welded to the ROS for irradiating an effect of, the tissue, and-permeable cells exceeds oxide (superoxide), H2 O2 and other having an active oxygen dihydroethidium (DHE), which turns into fluorescent in the presence of oxidizing agents including for dying been. I/R violet fluorescence detection to a strong damage ROS as certification by etching the planarizing layer and the production of excessive amounts. Creating a ROS BRAP and HBA but inhibited by a both, on the formation of a ROS than the BRAP HBA the restraining using the higher. I/R damage due number of positive cells in addition a strong TUNEL (terminal deoxynucleotidyl transterase dUTP nick end labeling) severe as identified by etching the planarizing layer and the apoptosis-between. HBA in self-destruction company cells of the liver (modest) of the normal for slot, by using a time hopping to the typical using the inhibitors, the BRAP doses of such as vibrationally significant than HBA (anti-apoptotic) using the greater harbor dues gun self-destruction company. Histological found according to, a serum I/R ALT (alanine transaminase) in between as measuring by an increased by etching the planarizing layer and the damage (also 5b). The BRAP I/R introduced into the concentration dependent fashion protection against damage between treatment of osteoporosis have demonstrated (protection). The HBA BRAP strong much less than (potent protective effect) that are at a preventing activity effect. Furthermore, property and antiinflammatory harbor dues gun self-destruction company of BRAP in addition cut caspase-3 and TNF-α protein expression of been estimated by measuring level. Cut tubes HBA TNF-α and caspase-3 the inhibitory effect of that are at a minimum the. While, such as doses of BRAP TNF-α the caspase-3 and a significant activity (also 5c-5d) show potent inhibition of was. In said in vitro results, in mouse model damage I/R between apoptosis and anti anti-inflammatory BRAP show characteristics. Effect of BRAP in model damage I/R surface of the heart In addition the effects of said beneficial BRAP I/R surface of the heart once the presence of a damaged been using the in vivo mouse model. 45 minutes after ischemia, BRAP (1.5 mg/kg) or vehicle i the reperfusion at the time. P been administered, then daily (1.5 mg/kg) was administered daytime 2. For functional resolution surface of the heart, PV (pressure-volume) loop (loop) measurement and Echocardiographic 2 week post-surgical I/R is been embodiment. PV (pressure-volume) loop (loop) analysis, 2 weeks after damage I/R, heart ef (cardiac output (CO)), ((EF) ejection fraction) pak the coefficient which it will dance and SW (stroke work) explore significance using the reduction of the (also 10a-10b and 6a). Additional using Echocardiographic cardiac functional resolution of the in addition, after surgical I/R 2 main lands in a compartment shortened rate (fractional shortening (FS)) using the reduction of the explore significance (also 10c). Administration of BRAP, in both Echocardiographic analysis and PV (pressure-volume) loop (loop), I/R-induced heart dysfunction vibrationally significantly reduced. The present studies have I/R after, such as oxidative stress is of beneficial BRAP, inflammatory, and associated reduction and apoptosis found if there is been performed to. These mechanical analysis the surface of the heart 24 time after damage I/R been performed in heart tissue. ROS BRAP by removing to search for the effect antioxidant, DHE (dihydroethidium) after I/R dyeable been used as an indicator of generating ROS. ROS mouse processing vehicle creation of a vibrationally significant after I/R been increased in group (also 6b). The significance of dyeing DHE BRAP administration to synchronize the part recessed from the conductive surface, after I/R BRAP welded to the ROS have shown removed from the CVD apparatus. Furthermore, the inflammatory response, TNF-α and mononuclear cell chemotaxis, protein -1 (monocyte chemotactic protein 1, MCP-1) layer have significant level of mRNA increased been it is shown (also 6c, 11a and 11b). BRAP administration of the vehicle-treated mouse, reduced expression of MCP-1 and TNF-α. I/R after, the pressure for assessing the effect harbor dues gun self-destruction company of BRAP, dyeing TUNEL assay and active caspase-3 been is performed. Apoptosis which is an index caspase-3 I/R activity up: the significance of after (also 6d). Activity of the BRAP capse-3 as efficient. Furthermore, 24 I/R of the significance of a cardiac myocyte-positive TUNEL period of time following a by increased the implementation certification, I/R the myocardial cells and regulating the apoptosis (cardiomyocyte apoptosis) has been increasing, the BRAP in an efficient way by means of been inhibited by the (also 6e-6f). Said results are, BRAP processing from oxidative stress by preventing a and irritations caused I/R and effectively prevents the of cardiac injury in the vola-tile certification the apoptosis-inhibitors. The toxic effect ofBRAP The toxic effect accumulated of the interim of BRAP for localizing the, BRAP (kg/day/1.5 mg) was administered daily in copper 7 to a mouse. Serum to the functions of the kidney and between 7 tests the significance of even after a anomaly detection got out of sight (also 7a-7b). Furthermore, after administering BRAP during 7, other organ for toxicity accumulated even the significance of a histological evidence cannot. (Also 7c). Said BRAP are observed in in vivo is to have good therapeutic dose for diversifying a safety the certification. 4 - (1, 3, 2- d jade company barley difficulty-2-one) phenylmethanol(4 - (1, 3, 2-Dioxaborinan-2-yl) phenyl) methanol) synthesis of 4 - (hydroxymethyl) phenyl boronic acid ((4 - (hydroxymethyl) phenyl) boronic acid) THF added to the suspension (suspension) are formed at the suspension been added. 1,2-propanediol 24 . 24 period of time following he shook his time, been clear said mixture. Furthermore, sodium sulfate been added (Sodium sulfate), he shook his time in addition 24 said mixture. After filter, said product (product) for solvent using a rotating solenoid been isolated from (rotary evaporator). Said raw product (crude product) the column been chromatography (ethylate: hexane = 2:3) (reference 12 also). 4 - (1, 3, 2-2-d jade company barley difficulty) phenylmethanol(4 - (1, 3, 2-Dioxaborinan-2-yl) phenyl) methanol) byH2O2removing Boronate (Boronate) compounds H2 O2 removing ability, [...] including diphenyl oxalate (diphenyl oxalate) for (rubrene) chemiluminescent of solution is evaluated as through which the light beam can strength was. Said (boronate) boronate (1 µm, or 10 µm) the H2 O2 solution (10 µm) been added to. H2 O2 1 and after reaction minutes, diphenyl oxalate solution H2 O2 been metal added to the, said chemical intensity of the light emission (luminometer) a thermal level has been determined by using (Femtomaster FB 12, Zylux Corporation, TN, US; also 13). Said results are described wherein said of the following materials was carried out using the method. 4 - (hydroxymethyl) phenyl boronic acid ((4 - (hydroxymethyl) pheny) lboronic acid) and 2 - (hydroxymethyl-2-methyl propane -1,3-diol (2 - (hydroxymethyl) - 2-methylpropane-1,3-diol) trans polybutadiene with drying said mixture for ease of application (tetrahydrofuran) dissolving the which faces an mechanical at room temperature so that the (stirring). 24 the reaction mixture after reaction of time said were clear, Na2 SO4 has added. Said reaction is (overnight) been two during night at room temperature, solvent the evaporator. BRAP has silica gels chromatography been obtained using (hexane/ethyl acetate = 70/30). The BRAP been dissolved in PBS (pH 7.4) at concentrations of 1 mm, of 100 µm H2 O2 in the presence of, 37 °C been incubation in. The concentration of generated from BRAP HBA, UV apparatus for interfacing with an appropriate time to has been determined using (spectrometer). 3 - (4,5-dimethylthiazil-2yl) - 2,5-diphenyltetrazolium bromide (MTT) cells of [...] BRAP been performed to assessing the toxicity. NIH3T 3 cells in 24 well plate 1X105 cells/well been cultured into density, RAW 254.7 cells and in addition 24 well plate to HEK cells 2X105 cells/well are density. Cells 24 for to -80% of confluency are time. Cells been treated with varying amounts of BRAP, 24 are time. MTT solution each well of 100 μ L been divided, 4 time DMSO are generated as a result of. 200 μ L formazan determined each cement dispersing agent (formazan crystals) are been added well culture nor post-incubation minutes. 10,570 nm in absorbance microplate reader (Biotek Instrumnets, Winooski, VT) has been determined to. The control group of said activity of living cells may be even extinction and BRAP processing of cells has been determined by comparing the absorbance of cells. H2 O2 for removing the ability of BRAP, [...] (rubrene) for including after a with diphenyl oxalate (diphenyl oxalate), chemiluminescent strength through which the light beam can is evaluated as was. BRAP (1 µm, 5 µm, 10 µm, 20 µm) for H2 O2 solution (10 µm) the added to. H2 O2 and a 1,5 or 10 minutes after reaction, diphenyl oxalate solution H2 O2 been metal added to the, apparatus for recording/reproducing sound using chemical emission (luminometer, Femtomaster FB 12, Zylux Corporation, TN, US) has been determined using. Cells of 250 µm time 24 H2 O2 been pretreatment to, then 15 to BRAP and a HBA been processing minutes. For measuring the level of a ROS cell in the, cells been miunutes DCFH-DA to 15. Fresh cells been cleaned twice improves, confocal scanning microscope been analyzed. Between the operation I/R been performed from mouse male a main 12. Simply, been an anesthetic mouse, incision the very middle line debribement been is performed for the semiconductor device from overcurrent. Portal triad, the mobile phone confirms the biliary tree, the main [...] and [...], ischemic damage is approximately between 70% to be brought into mesenchymal below's right tumoral vasculature to (lobe) been fixed clip vascular except that the. 1 of time after ischemia, reperfusion blood vessel clip for relieving while been made. Sham group mouse vascular ligation (clamp) and signed off. The/surgical heart I/R Choudhury, et al. , 2011, Basic Res Cardiol 106:397 described as been performed from mouse male the main 12. Unloaded over surface, been an anesthetic mouse, rodent ventilator (ventilator) and put her in (model 687, Havard Respirator). After thoracotomy, left in the front of a down artery (LAD, left anterior descending artery) is ascertained and, a specialized 30G-catheter (catheter) in every to surround the silk 7-0 was-up for suturing the patient's eye. Ventilation and anesthetic of said under conditions (ventilation) in coordinate input 45 been two minutes, after said sealing line cutting and artery perfusion again by reconstruction said reperfusion have been made. A mouse surgical Sham such as without closed LAD undergo the rear side of the main unit. Surface of the heart function the pressure-volume loop analysis using Echocardiographic and a (pressure volume loop measurement) Lee, et al. , 2013, Sci, I/R Rep 3:2233 described as has been determined after 2 week. The right carotid artery generally pressure-volume variable enters into an oil (pressure volume parameters) a 1,4 Fr. micro-tip pressure volume catheter (1,4 Fr. micro-tip pressure-volume catheter) isoflurane (2%) using (Scisense Incm Ontario, Canada) has been determined after anesthetic shutdown. Said catheter (catheter) the, LV pharmacodynamic parameters blood flow to obtain had to dig down to sneaked coaxed inwardly brain alcoholic beverage left. Powerlab system data (ADInstruments, Colorado Springs, CO) been the recording. Heart (HR) body sealing, pak it will dance, quantity (SV), a (CO) ef heart (SW) pak the action which it will dance including the pulse variable volume pressure-pulse Cardiosoft pro software (Cardiosoft, Houston, TX) measured using been and analyzed. Cardiac ultrasound through a pectus excavatum repair MS400 converter (18-38MHz) (Visualsonics, Toronto, Canada) microwave Vevo2100 together with a small animal imaging system was is carried out by employing (Ultra-high frequency small animal imaging system). For rapidly cell death between, DeadEndTM fluorometric Tunel kit dyeable TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) (promega, Madison, WI) been performed using a. The nuclear (section) tissue compartments (4'-6-diamidino-2-phenylindole (DAPI) dyeing) nuclear and cell death (TUNEL dyeing) the n bit parallel data inputted strands of early filament of steel cord, confocal laser scanning microscope been analyzed using a. For heart tissue, the dyeing TUNEL in situ cell death detection kit, fluorescein (fluorescein) (Roche Applied Science, Indianapolis, IN) been carried out using the. Non from nuclear cardiac muscle cells to emits light to cardiac muscle cells, nuclear (DAPI dyeing) dyeing controller for wire bonder, of a centrifuge and a shaker with death (TUNEL dyeing) and cardiac muscle cells (α-Actinin dyeing) been is used, the compartments dyed been analyzed using a confocal microscopy. - 2000-nuclear/field and at least of -10 high power field was that each sample are calculated to. Caspase Caspase-3 the activity of the, Choudhury, et al. , 2011, Basic Res Cardiol 106:397; Bae, et al. , 2010, described as Am J Physiol Heart Circ Physiol 299 : H1374, of colorimetry kit method (colorimetric assay kit) to (R & D Systems, Minneapolis, MN) has been determined. Unloaded over surface, protein sample substrate in Acetyl-Asp-Glu-Val-Asp-p-nitroanilide been added to. Enzyme-catalyzed p-nitroanilide 405 nm has been determined in the release. For method for isolating the active PRAP, activity (colorimetric assay kit) kit method of colorimetry (R & D Systems, Minneapolis, MN) using, histone plate on protein coating (histone) by biotinylated poly (ADP-ribose) in 450 nm has been determined. Collected for molecular analysis are heart tissue, Bae, et al. , 2010, Am J physiol Heart Circ Physiol 299 : H1374 been analysis is carried out according to. RT-PCR 18S of ribosomal for the control group includes internally primers are all the n bit parallel data inputted act RT-PCR signals are, associated with 18S of RT product was-bit data to each cell signal. Blots for analysis [...], the inclusion protein has been determined using BCA rapidly. The tissue-building OCT (The optimal cutting temperature) been fixed to 4% paraformaldehyde. The tissue compartments 30 minutes in 37 °C with protection from light 5 µm dihydroethidium is moisture in the chamber was incubating the and a (DHE, Sigma-Aldrich). Furthermore, 4', been is applied 6-diamidino-2-phenylindole (DAPI). Images are confocal fluorescence microscopy been thus obtained. Been representation by ±SEM are average data. Groups within still other and is a comparison of the (San Diego, CA) using Graphpad prism 5.0 unpaired Student t-tests and a repeated ANOVA been performed by azimuth measurement. <0.05 of been considering that the significance of the p-values. Elongation at ischemia/reperfusion(IR) that is inverse from the effect of orally BRAP damage Parenterally administered BRAP I/R stretched in mouse has been experiment in model damage. In said model, mouse during clamping unique one of the (contralateral nephrectomy) discectomy elongated contralateral and (unilateral clamping) for a period of from about 30 minutes mixing of light with the coordinate input. Mouse has BRAP twice to been administered parenterally time points, : night before surgical, just before their surgical I/R. I/R of read markers was comprising: after reperfusion, level (Creatinine) creatinine of time 24 ; Chemotactic factor protein -1 (monocyte chemo-attractant protein-1) (MCP-1) TNF-α and monocytes (both inflammatory markers); DHE dyeing (monitoring generation ROS); and TUNEL dyeing (monitoring cell death, and). Said results are, BRAP a the daily administration of parenterally (8 mg/kg) once the presence of a damaged I/R elongation at after 4 is renal function in model explore significance have been shown to exhibit an improved result been (also 14). Furthermore, as described in the present invention, inflammatory marker, MCP-1 and TNF-α BRAP of the activity of the been relief results in a significant by administration parenterally (also 15). A marker of generating ROS, DHE dyeing (also 16) a marker of and cell death, in addition BRAP TUNEL dyeing (also 17) are according to oral administration of been significantly reduce the. Wherein each and all patent citation, a disclosure and patent application disclosure are, in all their thereby may be included wherein by referring to. Specific embodiment examples with reference to the present invention disclosure but, other embodiment of the present invention and examples of the present invention are modified pure and having a length range where a new file does not exist are practically non-separated sugar by methods well known in other by. is clear that can be of valid of. Examples claim with an embodiment all such are modified comparable to that containing is intended to be understood. The present invention provides an anti-inflammatory and antioxidant compound having phenyl boronic ester which has high specific reactivity to hydrogen peroxide capable of producing 4-hydroxyl benzyl alcohol. According to an embodiment, the compound of the present invention may be used in preventing and treating and/or inflammation including ischemic diseases. COPYRIGHT KIPO 2016 4 - (hydroxyl methyl) phenyl at step Nick S (4 - (hydroxymethyl) phenylboronic ester) According to Claim 1, the (boronic ester) nick S boronate said diol, triol, tetraol, pentaol, and higher hexaol chosen from the group comprising polyol further comprises at an alcohol phase, wherein said alcohol and (hydroxyl methyl) phenyl at step Nick acid 4 - (4 - (hydroxymethyl) phenylboronic acid) covalent bonding coupled to of the link is characterized by nick S boronate (boronic ester). According to Claim 2, including of said acid and alcohol are diol or triol nick S to characterized by boronate (boronic ester). According to Claim 3, said acid and alcohol are 1,3-propanediol or 2 - (hydroxymethyl) - 2-methylpropane-1, characterized by including a 3-diol nick S to boronate (boronic ester). According to Claim 1, the (boronic esters) boronate said nick S 4 - (5 - (hydroxymethyl) - 5-methyl-1, 3, 2-dioxaborinan-2-yl) phenyl methanol or 4 - (1, 3, 2-dioxaborinan-2-yl) phenyl methanol (boronic ester) characterized by including a boronate to nick S. Number 1 anti to number 5 anti either nick S boronate terms to microparticles characterized by including a (boronic esters). According to Claim 6, said microparticles to a polymer (polymer) microparticles characterized by including a (liposome), or liposome. According to Claim 7, said polymer (polymer) the poly (lactic acid) (PLA), poly (glycolic acid) (PGA), poly (lactic-co-glycolic acid) (PLGA), and poly (ε-caprolactone) (PCL) select at least one from the group comprising to characterized by including the microparticles. Number 1 anti to number 5 anti either nick S boronate terms to characterized by including a (boronic esters), such as oxidative stress radix and then pharmaceutical compositions. According to Claim 9, said nick S it shakes off boronate 4-hydroxybenxzyl alcohol (HBA) in the body in order to release at least a at least partially decomposed, is characterized by, such as oxidative stress radix and then pharmaceutical compositions.
According to Claim 9, said (Acute Coronary Syndrome) acute coronary syndrome, such as oxidative stress damage, ischemia between, elongation at ischemia, ischemia of the brain, coronary artery disease, right circuit alcoholic beverage resuscitation, systemic emptiness the characteristic which will break /reperfusion and/or vascular of associated with such as thromboembolic is ischemia/reperfusion injury, such as oxidative stress characterized by pharmaceutical composition for preventing and treating once the presence of a damaged. According to Claim 11, , such as oxidative stress radix and then said ischemic/reperfusion injury and associated cell death (apoptosis) or reduce an inflammatory reaction and once the presence of a damaged, such as oxidative stress characterized by the pharmaceutical composition for preventing and treating.
According to Claim 11, said treatment, such as oxidative stress radix and then inhibiting formation of ROS to or preventing, such as oxidative stress characterized by pharmaceutical composition for preventing and treating once the presence of a damaged. According to Claim 13, to the ROS Superoxide or peroxide species, such as oxidative stress characterized by including a pharmaceutical composition for preventing and treating once the presence of a damaged.
According to Claim 9, said treatment, such as oxidative stress radix and then, during transplantation of tissues or organs before and after or implantation, tissue or organ in ischemic damage or reperfusion injury, such as oxidative stress characterized by relates to an pharmaceutical composition for preventing and treating once the presence of a damaged. According to Claim 15, a heart tissue said tissues or organs, heart, kidney tissue, elongated, the liver tissue, liver, waste tissue, waste, pancreatic, the pancreatic tissue, bowel tissue, field, Thymus, bone, cartilage, muscle tissue, tendon, cornea, epithelial, tissue, skin, heart valve, neurons, neural, endothelial tissue, arterial or venous is characterized by, such as oxidative stress once the presence of a damaged pharmaceutical composition for preventing and treating. According to Claim 15, and is combined with the support body reperfusion damage or ischemic said said ischemic damage or cell death or associated with impaired reperfusion inflammatory, such as oxidative stress characterized by relates to an pharmaceutical composition for preventing and treating once the presence of a damaged. According to Claim 17, said cardiac to reduce the cell death, or of new nerve cells death, such as oxidative stress characterized by relates to an pharmaceutical composition for preventing and treating once the presence of a damaged.
According to Claim 18, said surface of the heart is a real Image and cell death, and PV loop by ultrasonic and/or a cardiac assays which evaluates the all forms of sulfur, and decreasing dysfunction surface of the heart, such as oxidative stress characterized by pharmaceutical composition for preventing and treating once the presence of a damaged. According to Claim 17, the to reduce the inflammatory said TNF-α a nitric oxide and/or induced to reducing the level of synthesis, such as oxidative stress characterized by pharmaceutical composition for preventing and treating once the presence of a damaged. According to Claim 17, the inflammatory cell death or said, acute coronary syndrome (Acute Coronary Syndrome), ischemia between, elongation at ischemia, ischemia of the brain, coronary artery disease, right circuit alcoholic beverage resuscitation, systemic emptiness the characteristic which will break /reperfusion and/or vascular of inflammatory cell death or associated with thromboembolic is characterized by, such as oxidative stress once the presence of a damaged pharmaceutical composition for preventing and treating.
According to Claim 6 characterized by including microparticles, such as oxidative stress once the presence of a damaged to pharmaceutical composition for preventing and treating. Number 1 anti to number 5 anti either nick S boronate to terms (boronic esters) characterized by including a drug delivery system. According to Claim 6 to including microparticles characterized by drug delivery system. Pharmaceutical composition according to Claim 9 including drug delivery system.
